...
首页> 外文期刊>PPAR research >Crosstalk between MicroRNAs and Peroxisome Proliferator-Activated Receptors and Their Emerging Regulatory Roles in Cardiovascular Pathophysiology
【24h】

Crosstalk between MicroRNAs and Peroxisome Proliferator-Activated Receptors and Their Emerging Regulatory Roles in Cardiovascular Pathophysiology

机译:MicroRNAS和过氧化物体增殖物激活的受体之间的串扰及其在心血管病理生理学中的新出现的调节作用

获取原文
获取原文并翻译 | 示例
           

摘要

Peroxisome proliferator-activated receptors (PPARs) play vital roles in cardiovascular pathophysiology, such as energy balance, cell proliferation/apoptosis, inflammatory response, and adipocyte differentiation. These vital roles make PPARs potential targets for therapeutic prevention of cardiovascular diseases (CVDs). Emerging evidence indicates that the crosstalk of microRNAs (miRNAs) and PPARs contributes greatly to CVD pathogenesis. PPARs are inhibited by miRNAs at posttranscriptional mechanisms in the progress of pulmonary hypertension and vascular dysfunction involving cell proliferation/apoptosis, communication, and normal function of endothelial cells and vascular smooth muscle cells. In the development of atherosclerosis and stroke, the activation of PPARs could change the transcripts of target miRNA through miRNA signalling. Furthermore, the mutual regulation of PPARs and miRNAs involves cell proliferation/apoptosis, cardiac remodeling, and dysfunction in heart diseases. In addition, obesity, an important cardiovascular risk, is modulated by the regulatory axis of PPARs/miRNAs, including adipogenesis, adipocyte dysfunction, insulin resistance, and macrophage polarization in adipose tissue. In this review, the crosstalk of PPARs and miRNAs and their emerging regulatory roles are summarized in the context of CVDs and risks. This provides an understanding of the underlying mechanism of the biological process related to CVD pathophysiology involving the interaction of PPARs and miRNAs and will lead to the development of PPARs/miRNAs as effective anti-CVD medications.
机译:过氧化物体增殖物激活的受体(PPAR)在心血管病理学生理学中起重要作用,例如能量平衡,细胞增殖/凋亡,炎症反应和脂肪细胞分化。这些重要作用使PPAR潜在目标用于治疗心血管疾病(CVDS)。新兴的证据表明microRNA(miRNA)和PPAR的串扰大大对CVD发病机制有贡献。 MiRNA在肺动脉高压和血管功能障碍进展中抑制了PPAR,涉及细胞增殖/凋亡,通信和内皮细胞的正常功能和血管平滑肌细胞的血管功能障碍。在动脉粥样硬化和中风的发展中,PPAR的激活可以通过miRNA信号传导来改变靶miRNA的转录物。此外,PPAR和MIRNA的相互调节涉及细胞增殖/细胞凋亡,心脏重塑和心脏病的功能障碍。此外,肥胖症是一种重要的心血管风险,由PPARS / miRNA的调节轴调节,包括脂肪组织中的脂肪发生,脂肪细胞功能障碍,胰岛素抗性和巨噬细胞极化。在本综述中,在CVDS和风险的背景下总结了PPAR和MIRNA的串扰及其新兴的监管角色。这为了解与涉及PPAR和MIRNA相互作用的CVD病理生理学相关的生物学过程的潜在机制,并将导致PPARS / MIRNA作为有效的抗CVD药物的发展。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号